Literature DB >> 19465164

Structural biology of the GAD autoantigen.

Gustavo Fenalti1, Ashley M Buckle.   

Abstract

For the past twenty years the type 1 diabetes autoantigen glutamic acid decarboxylase (65 kDa isoform; GAD65) has become a prototypic autoantigen, yielding a wealth of immunological and clinical insights. However for most of that period, much of the data could not be placed in a structural context, and relied upon modelling 'guess-work'. The high-resolution crystal structure of GAD65, as well as that of its isoform GAD67, was determined in 2007, providing many insights into the molecular determinants of antigenicity, as well as an atomic positioning of the epitope-mapping data. Despite the two isoforms having the same fold and high sequence identity, it is intriguing that only the 65 kDa isoform functions as an autoantigen. The structures shed much light on this question, revealing striking differences in structure and mobility at the C-terminal domain of the isoforms, which agreed with remarkable accuracy with epitope-mapping data. Furthermore the structures provided an explanation of why two enzymes are required to catalyse the same reaction in mammals, and how this might be linked to their contrasting antigenicities. This review thus focuses on how the GAD system represents a unique testbed for understanding the relationships between molecular structure, function and antigenicity. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19465164     DOI: 10.1016/j.autrev.2009.05.003

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  9 in total

1.  Cofactor-dependent conformational heterogeneity of GAD65 and its role in autoimmunity and neurotransmitter homeostasis.

Authors:  Itamar Kass; David E Hoke; Mauricio G S Costa; Cyril F Reboul; Benjamin T Porebski; Nathan P Cowieson; Hervé Leh; Eugenia Pennacchietti; Julia McCoey; Oded Kleifeld; Carla Borri Voltattorni; David Langley; Brendan Roome; Ian R Mackay; Daniel Christ; David Perahia; Malcolm Buckle; Alessandro Paiardini; Daniela De Biase; Ashley M Buckle
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

Review 2.  Islet autoantigens: structure, function, localization, and regulation.

Authors:  Peter Arvan; Massimo Pietropaolo; David Ostrov; Christopher J Rhodes
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

3.  GAD65 autoantibodies and its role as biomarker of Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA).

Authors:  Roberto Towns; Massimo Pietropaolo
Journal:  Drugs Future       Date:  2011-11       Impact factor: 0.148

4.  An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.

Authors:  Bindu Jayakrishnan; David E Hoke; Christopher G Langendorf; Ashley M Buckle; Merrill J Rowley
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

5.  Characterisation of peptide microarrays for studying antibody-antigen binding using surface plasmon resonance imagery.

Authors:  Claude Nogues; Hervé Leh; Christopher G Langendorf; Ruby H P Law; Ashley M Buckle; Malcolm Buckle
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

6.  Evolution, immunity and the emergence of brain superautoantigens.

Authors:  Serge Nataf
Journal:  F1000Res       Date:  2017-02-21

Review 7.  Neurological Syndromes Associated with Anti-GAD Antibodies.

Authors:  Maëlle Dade; Giulia Berzero; Cristina Izquierdo; Marine Giry; Marion Benazra; Jean-Yves Delattre; Dimitri Psimaras; Agusti Alentorn
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

Review 8.  Neuropsychiatric Disorders Due to Limbic Encephalitis: Immunologic Aspect.

Authors:  Yu-Chia Kao; Ming-I Lin; Wen-Chin Weng; Wang-Tso Lee
Journal:  Int J Mol Sci       Date:  2020-12-31       Impact factor: 5.923

9.  PLP-dependent enzymes.

Authors:  Alessandro Paiardini; Roberto Contestabile; Ashley M Buckle; Barbara Cellini
Journal:  Biomed Res Int       Date:  2014-01-15       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.